PHILADELPHIA – Researchers at the School of Medicine discovered that proteins carrying chemical cargo in nerve cells react differently when exposed to the tau protein, which plays an important role in Alzheimer’s disease.
Dynein and kinesin proteins transport cellular cargo towards opposite ends of tracks called microtubules. Tau binds to the microtubule surface and acts like a speed bump to regulate protein traffic, the group found. “But it is a smart speed bump because it impedes these different motor proteins to different degrees,” explains first author Ram Dixit, PhD, a postdoctoral fellow in the lab of senior author Erika Holzbaur, PhD, Professor of Physiology.
Click on thumbnail
to view full-size image
“Our findings show a mechanism of regulating the transport of nutrients, signaling molecules, and waste proteins along a nerve cell’s axon,” says Dixit. “Neurodegenerative diseases such as Alzheimer’s arise when pieces of this shipping system goes awry.”
The transport performed by dynein and kinesin is required for continuously providing new proteins to the axon and synapse to maintain normal cellular function, and is also required to remove old, misfolded, or aggregated proteins for degradation. Just as important, this transport is required for moving other proteins from the nerve-cell synapse back to the cell body, which is also required to maintain healthy neurons.
In neurons, microtubules are abundantly decorated with tau. Dynein and kinesin encounter the tau molecules on their travels along the microtubules. The Penn group found that dynein, which carries loads towards the interior of the cell, maneuvers around tau; whereas, kinesin, which carries loads towards the outside of the cell, detaches when it encounters tau.
These findings appear online January 17 in Science in advance of print publication.
Dynein and kinesin’s individual maneuverings when encountering tau allow for the cell to be able to offload cargo where it needs to go with fine-tune accuracy. “Tau may determine where kinesin offloads cargo along the microtubule tracks that radiate out to the cell surface from the center,” says Holzbaur. “And dynein’s ability to back up and go around when it encounters an obstacle such as tau may be a mechanism to ensure that it gets to the center of the cell with its important cargo.”
The group conducted studies using single molecules moving along a tau-decorated microtubule to determine the effects of tau on dynein and kinesin’s movement. Mutations in molecular motors such as dynein and kinesin can lead to degeneration of neurons. These mutations, for example, decrease the efficiency of dynein and kinesin. This problem can lead to the accumulation of misfolded proteins in the cell, which, in turn may lead to the degeneration of the neuron.
“There’s a growing theme that defects in transport are tightly associated with neurodegeneration,” says Holzbaur. “It’s already been shown in Alzheimer’s disease that there is a change in the distribution of tau along microtubules. Instead of kinesin getting its cargo closer to the cell’s outer surface, tau accumulates in the cell body and kinesin’s cargo of newly synthesized proteins gets dropped early, not at the cell surface, thus causing problems. Our findings explain how that can happen.”
Co-authors are Yale E. Goldman, MD, PhD, Director of the Pennsylvania Muscle Institute, and Jennifer L. Ross, PhD, a postdoctoral fellow in the Holzbaur lab now at the Department of Physics at the University of Massachusetts, Amherst.
This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Disease and the National Science Foundation.
This release, still image, and videos of dynein and kinesin movement can be found at www.pennhealth.com/news.
PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #3 in the nation in U.S. News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.